BioVersys AG
BIOV.SWDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
BV100 (300 mg)
Hospital Acquired Bacterial Pneumonia (HABP)
BV100 plus Polymyxin B
Ventilator Associated Pneumonia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BV100 (300 mg) | Phase 3 | Hospital Acquired Bacterial Pneumonia (HABP) | - | - |
BV100 plus Polymyxin B | Phase 2 | Ventilator Associated Pneumonia | - | - |
Frequently asked questions
What is in BioVersys AG's drug pipeline?→
CatalystAlert tracks 2 drug candidates in BioVersys AG's (BIOV.SW) pipeline across Phase 3, Phase 2. Its lead program is BV100 (300 mg) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BioVersys AG's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for BioVersys AG (BIOV.SW) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track BIOV.SW biotech catalysts?→
Add BIOV.SW to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BioVersys AG's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.